Watson gets FDA approval for generic Yasmin
MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.
Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.
Watson said it has started shipping the drug, though Bayer’s patent litigation suit against the company concerning the drug remains pending in the U.S. District Court for the Southern District of New York.
Yasmin and generic versions had sales of around $97 million during the 12 months ended in June, according to IMS Health.
Greenstone to launch Authorized Generics Alliance
PEAPACK, N.J. The generics subsidiary of Pfizer is launching a new business focused on authorized generics.
Greenstone announced Tuesday the launch of the Authorized Generics Alliance, which it said would combine its business model and 17 years of experience in the generics market with the expertise of other drug makers to market authorized generics in the United States under the Greenstone label.
“Greenstone is one of the longest-running and most respected marketers of innovator-authorized generics in the United States,” Greenstone general manager Michael Sweitzer said. “As part of Pfizer, Greenstone has the backing of the company’s 161-year expertise in innovation, integrity, quality and supply reliability.”
Unlike generic drugs, which are approved under an abbreviated regulatory approval process by the Food and Drug Administration after the branded drug company’s market exclusivity has expired and compete with their branded counterparts, authorized generics are branded drugs sold under their generic names with permission from the branded drug maker, often through third-party companies.
ProPhase Labs picks agency of record
DOYLESTOWN, Pa. ProPhase Labs on Tuesday announced it has retained media solutions company Women’s Marketing as its agency of record. The agency will work closely with ProPhase Labs to develop and implement high-impact media campaigns for Cold-Eeze and Kids-Eeze across a variety of networks, the company stated.
The ad campaigns coincide with improvements to Cold-Eeze and Kids-Eeze product and packaging, including a Kids-Eeze line of symptom relievers in a "chew" form.
“ProPhase Labs has been working hard to further improve our current product lines and bring new, effective products to market,” stated Ted Karkus, ProPhase CEO. “We are excited to join with WMI to create a dynamic media campaign that will introduce our new and improved products to new consumers and reinvigorate our loyal customers.”